Sulfhydryl-Modified Polyurethane Foams for Wound Healing

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current wound dressings used in negative pressure wound therapy are biologically inert and lack the ability to deliver or capture biologically active components, limiting their therapeutic potential for enhanced wound healing.

Innovation Solution

Development of sulfhydryl-modified polyurethane foams that can bind biologically active components such as metals and polypeptides, allowing for the delivery and capture of therapeutic agents and potentially conducting electrical currents for improved wound healing.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Adaptability or versatility

If biologically inert polymer foams are used for negative pressure wound therapy, then the device structure is simple and manufacturing is easy, but the therapeutic potential is limited due to inability to deliver or capture biologically active components

Engineering Contradiction:
Improvetherapeutic potentialVSAvoiddevice complexity
Core Design Contradiction:
Adaptability or versatilityVSDevice complexity

Solution Approach 1:

The polymer foam is chemically modified by introducing sulfhydryl functional groups through copolymerization or surface treatment. This parameter change transforms the inert polymer into a reactive material capable of binding metals and biologically active components, thereby enhancing therapeutic potential while maintaining the fundamental foam structure

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The invention creates a composite material system where sulfhydryl-functionalized polymer foam serves as the base matrix, integrated with metals (such as silver, copper, or zinc) and biologically active components (such as growth factors or antibiotics). This composite structure combines the mechanical properties of foam with the therapeutic functions of embedded materials

Inventive Principle:
Principle #40Composite materials

2Adaptability or versatility

If sulfhydryl-modified polymers are used to bind biologically active components, then the ability to deliver and capture therapeutic agents is improved, but the manufacturing process becomes more complex

Engineering Contradiction:
Improveability to bind biologically active componentsVSAvoidease of manufacture
Core Design Contradiction:
Adaptability or versatilityVSEase of manufacture

Solution Approach 1:

The sulfhydryl functional groups are introduced into the polymer structure during the foam manufacturing process itself, rather than as a separate post-processing step. This preliminary action ensures uniform distribution of reactive groups throughout the foam matrix and simplifies subsequent steps for incorporating therapeutic agents

Inventive Principle:
Principle #10Preliminary action

Solution Approach 2:

The sulfhydryl functional groups act as intermediary binding sites that facilitate the attachment of biologically active components. These reactive groups serve as a bridge between the inert polymer matrix and the therapeutic agents, enabling controlled release and capture mechanisms

Inventive Principle:
Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The sulfhydryl-modified foams enhance wound healing by delivering therapeutic agents, capturing harmful proteases, and providing electrical stimulation, thereby accelerating tissue growth and reducing edema, while also being capable of conducting electrical currents to promote epithelialization.

Implementation Method 1

such modified polymers can, in some aspects, be used to bind biologically active components or agents, such as metals and/or polypeptides to the device

Methodology Applied
Scientific EffectChemical bonding: Chemical Bonding

Data Source

PatentEP2912088B1Sulfhydryl-functionalized polymeric compositions for medical devices
Publication Date: 2019.09.18 KCI LICENSING INC
  • EP2912088B1 patent drawingFigure 1
  • EP2912088B1 patent drawingFigure 2
  • EP2912088B1 patent drawingFigure 3

AI summary

The present disclosure provides sulfhydryl-modified polymer foams, which may be used for wound dressing materials. For example, the modified materials can include free sulfhydryl group, which can serve as a linker to attach biologically active molecules. For example, sulfhydryl groups can be used to conjugate biologically active polypeptides and/or metals to foam polymers. Methods for using sulfhydryl-modified polymers, such as for wound dressings, are also provided.